Show Summary Details
Page of

Immunotherapy in Melanoma 

Immunotherapy in Melanoma
Immunotherapy in Melanoma

Maggie Diller

and Ragini R. Kudchadkar

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 13 July 2020

Immune therapies have revolutionized the treatment of metastatic melanoma, and more patients are now long-term survivors of this disease. Questions still remain regarding the best sequencing and combination of treatments. Additionally, studies are underway to identify biomarkers that may serve as predictors of response and help further guide and individualize therapy. With regard to adjuvant treatment, interferon remains the standard of care. However, given the impact of immunomodulation on stage IV disease and early studies suggesting the efficacy of such medications as ipilimumab as adjuvant therapy, results from ongoing trials may change the way we treat patients in the adjuvant setting. Toxicities for the various medications can be expansive. Early recognition and management of adverse events is key to the safe and effective use of all therapies and in preventing long-term morbidity and mortality.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.